Association of Prediagnostic Blood Metabolomics with Prostate Cancer Defined by ERG or PTEN Molecular Subtypes.
Journal
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
17
09
2020
revised:
24
11
2020
accepted:
19
02
2021
pubmed:
26
2
2021
medline:
13
1
2022
entrez:
25
2
2021
Statut:
ppublish
Résumé
The The study was performed among 277 prostate cancer cases with ERG status, 211 with PTEN status, and 294 controls nested in the Health Professionals Follow-up Study (HPFS) and the Physicians' Health Study (PHS). We profiled 223 polar and non-polar metabolites using LC-MS in prediagnostic plasma specimens. We applied enrichment analysis and multinomial logistic regression models to identify biological metabolite classes and individual metabolites associated with prostate cancer defined by ERG or PTEN status. Compared with noncancer controls, sphingomyelin ( The molecular process of prostate carcinogenesis may be distinct for men with different metabolomic profiles. These novel findings provide insights into the metabolic environment for the development of prostate cancer.
Sections du résumé
BACKGROUND
The
METHODS
The study was performed among 277 prostate cancer cases with ERG status, 211 with PTEN status, and 294 controls nested in the Health Professionals Follow-up Study (HPFS) and the Physicians' Health Study (PHS). We profiled 223 polar and non-polar metabolites using LC-MS in prediagnostic plasma specimens. We applied enrichment analysis and multinomial logistic regression models to identify biological metabolite classes and individual metabolites associated with prostate cancer defined by ERG or PTEN status.
RESULTS
Compared with noncancer controls, sphingomyelin (
CONCLUSIONS
The molecular process of prostate carcinogenesis may be distinct for men with different metabolomic profiles.
IMPACT
These novel findings provide insights into the metabolic environment for the development of prostate cancer.
Identifiants
pubmed: 33627383
pii: 1055-9965.EPI-20-1363
doi: 10.1158/1055-9965.EPI-20-1363
pmc: PMC8102317
mid: NIHMS1678985
doi:
Substances chimiques
Biomarkers, Tumor
0
ERG protein, human
0
Transcriptional Regulator ERG
0
PTEN Phosphohydrolase
EC 3.1.3.67
PTEN protein, human
EC 3.1.3.67
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1000-1008Subventions
Organisme : NCI NIH HHS
ID : K99 CA248335
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA090381
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR002542
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA167552
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA006516
Pays : United States
Informations de copyright
©2021 American Association for Cancer Research.
Références
Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):1984-93
pubmed: 23983239
Neoplasia. 2010 Jul;12(7):590-8
pubmed: 20651988
BMC Med. 2016 Jan 28;14:13
pubmed: 26817443
Am J Epidemiol. 2017 Dec 15;186(12):1352-1361
pubmed: 28633309
BMC Med. 2020 Jul 23;18(1):187
pubmed: 32698845
Nat Med. 2014 Oct;20(10):1193-1198
pubmed: 25261994
Front Endocrinol (Lausanne). 2019 Aug 21;10:577
pubmed: 31496996
Mol Biosyst. 2015 Dec;11(12):3397-406
pubmed: 26474270
Diabetes. 2004 May;53(5):1215-21
pubmed: 15111489
Metabolomics. 2014 Oct 1;10(5):1036-1041
pubmed: 25254003
Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1497-509
pubmed: 22736790
PLoS One. 2012;7(11):e48889
pubmed: 23152813
Cancer Res. 2016 Apr 15;76(8):2288-2300
pubmed: 26921328
Am J Clin Nutr. 2016 Mar;103(3):851-60
pubmed: 26817504
Eur Urol Oncol. 2021 Feb;4(1):56-65
pubmed: 31378665
Diabetes Metab Res Rev. 2009 Jan;25(1):3-12
pubmed: 19145587
Cancer Epidemiol Biomarkers Prev. 2018 Feb;27(2):193-200
pubmed: 29167279
Clin Chem. 2013 Nov;59(11):1657-67
pubmed: 23897902
Am J Prev Med. 1991 May-Jun;7(3):150-4
pubmed: 1931143
Eur Urol. 2019 Jul;76(1):33-40
pubmed: 30301696
JAMA. 1993 Feb 17;269(7):873-7
pubmed: 8426446
Am J Epidemiol. 2015 May 1;181(9):706-13
pubmed: 25852077
Clin Cancer Res. 2020 Mar 1;26(5):1086-1093
pubmed: 31754047
J Natl Cancer Inst. 2015 Nov 27;108(2):
pubmed: 26615022
Int J Cancer. 2015 Nov 1;137(9):2124-32
pubmed: 25904191
Cancer Epidemiol Biomarkers Prev. 2016 May;25(5):745-9
pubmed: 26941365
Br J Cancer. 2016 Oct 25;115(9):1087-1095
pubmed: 27673363
Nat Genet. 2009 May;41(5):509-10
pubmed: 19399032
Int J Cancer. 2019 Dec 15;145(12):3231-3243
pubmed: 30779128
Clin Cancer Res. 2011 Oct 15;17(20):6563-73
pubmed: 21878536
BMC Genomics. 2008 Jul 31;9:363
pubmed: 18671852
Am J Epidemiol. 1990 Jun;131(6):1068-71
pubmed: 2343859
Diabetes Care. 2016 May;39(5):833-46
pubmed: 27208380
Int J Cancer. 2014 Jan 1;134(1):197-206
pubmed: 23797698
Cancer Cell Int. 2018 Nov 12;18:177
pubmed: 30459527
BMC Med. 2017 Jul 5;15(1):122
pubmed: 28676103
Cell. 2015 Nov 5;163(4):1011-25
pubmed: 26544944
J Natl Cancer Inst. 2013 Dec 18;105(24):1881-90
pubmed: 24292212
J Am Acad Dermatol. 2000 Jun;42(6):1003-7
pubmed: 10827403
Int J Clin Exp Med. 2015 Apr 15;8(4):5430-7
pubmed: 26131120
Endocr Res. 2015;40(1):54-61
pubmed: 25105463
Science. 2005 Oct 28;310(5748):644-8
pubmed: 16254181
Mod Pathol. 2008 Dec;21(12):1451-60
pubmed: 18500259
J Natl Cancer Inst. 2011 Jun 8;103(11):876-84
pubmed: 21586702
Arterioscler Thromb. 1993 Nov;13(11):1587-92
pubmed: 8218099
Int J Cancer. 2020 Feb 1;146(3):720-730
pubmed: 30951192